TRANS-NET · Identification of genomic and biological markers as predictive/diagnostic/therapeutic tools for use in allogeneic stem cell transplantation: translational research towards individualised patient medicine
FP6 — Marie Curie Actions (Human Resources and Mobility)
- Duration
- 2005-01-01 → 2009-06-30
- EU contribution
- €4,539,456
- Participants
- 13
- Scheme
- EIF
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Results in brief
Final Activity Report Summary - TRANS-NET (Identification of genomic and biological markers as predictive/diagnostic/therapeutic tools for use in allogeneic stem cell transplantation ...)
The Marie Curie (MC) research training network, TRANS-NET has enabled the training of a European wide consortium of early stage and experienced researchers in a wide range of techniques and disciplines of value to clinical research as a hole but also to academia and industry. The MC fellows were trained via various workshops and within laboratories in molecular biology cellular immunology, statistics and immunobiology. The work of the project has culminated in a number of PhD theses papers and scientific communications and has developed new tools (biomarkers - genetic and biological) for assessment of outcome of haemopoietic stem cell transplantation. Via animal model experiments and clinical assessments of patients suffering from complication of the transplant new markers for early identification of either relapse of the disease post-transplant and / or early diagnosis of complaints such as graft versus host disease (where the donor cells within the transplant graft attacks the patient) have been developed.
Data: CORDIS, © European Union
Project objective
Allogeneic stem cell transplantation (HSCT) is a life saving therapy for haematological disorders (leukaemia and lymphoma, inherited immune disorders, and aplastic anaemia). Over 7000 such transplants are carried out each year in Europe. However the over all survival rate after HSCT is poor (40-60%), and cure of patients is hampered by clinical complications that arise post-transplant; largely due to genetic and biological differences which exist between a given patient and donor. These differences includ e transplantation antigens (major and minor histocompatibility antigens). Pioneering research by Partners, have indicated that a number of non-HLA gene polymorphisms also affect the severity and incidence of transplant related complications. There is an urgent need to improve patient-donor matching at both the biological and genomic level which would develop HSCT beyond the current state of the art. HSCT outcomes will be improved if predictive assays, diagnostic tools and new therapeutics were developed and ultimately used by HSCT clinicians for individual patient based medicine. TRANS-NET teams have expertise in predictive bioassays, genomics, diagnostics and novel therapeutics who will train researchers in the key technologies of, mRNA expression profi ling, pathology, non-HLA immunogenetics and mechanisms of immune recognition; with the ultimate aim of applying the results of TRANS-NET in the HSCT clinical setting. TRANS-NET aims to 1) Define new biological/genomic indicators and novel therapies for th e potential development of new clinical strategies for improving the outcome and quality of life of HSCT patients. 2) Develop unique training programmes in genomics and immunobiology of transplantation and generate highly trained scientists with the abili ty to manage complex projects and understand the scientific challenges of individualised patient medicine. 3) Disseminate knowledge gained throughout the ERA and clinical HSCT centres across the EC.
Original text from CORDIS.
Participants
- UNIVERSITY OF NEWCASTLE UPON TYNE · NEWCASTLE UPON TYNECoordinatorUnited Kingdom
- BEREICH HUMANMEDIZIN ? GEORG-AUGUST-UNIVERSITY GOETTINGEN · GOETTINGENGermany
- CHARLES UNIVERSITY PRAGUE · PRAHA 2Czechia
- GSF - FORSCHUNGSZENTRUM FüR UMWELT UND GESUNDHHEIT, GMBH · NEUHERBERGCity levelGermany
- HEINRICH-HEINE-UNIVERSITäT DüSSELDORF · DUSSELDORFCity levelGermany
- HLA ET MEDECINE · PARISCity levelFrance
- KLINIKUM DER UNIVERSITäT REGENSBURG · REGENSBURGCity levelGermany
- MEDICAL UNIVERSITY OF VIENNA · VIENNAAustria
- TECHNISCHE UNIVERSITAET MUENCHEN - KLINIKUM RECHTS DER ISAR · MUNICHCity levelGermany
- THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (HERINAFTER CALLED TCD) · DUBLINIreland
- UNIVERSITETET I OSLO · OSLONorway
- UNIVERSITY OF GENEVA · GENEVESwitzerland
- UNIVERSITY OF GLASGOW · GLASGOWUnited Kingdom
Links
Data: CORDIS, © European Union